Elevated serum α-synuclein levels in Huntington’s disease patients
Objective: To investigate serum α-synuclein levels in Huntington’s disease (HD) patients. Background: HD is a heredodegenerative disease caused by mutations in HTT coding for huntingtin…Levels of plasma alpha-synuclein as measured using Single Molecule Array technology is higher in Parkinson’s disease compared to controls and is not influenced by LRRK2 genotype
Objective: To investigate plasma alpha-synuclein levels in PD using ultra-sensitive protein detection technology, and to determine the association of plasma alpha-synuclein with cognitive, motor and…Salivary Alpha-Synuclein a new tool for the diagnosis of Parkinson’s disease?
Objective: The aim of the PARKSYN study was to test the utility of salivary alpha-synuclein (a-syn) concentration in the differential diagnosis between Parkinson's disease (PD)…Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration
Objective: To determine the relationship between synucleinopathy, neuroinflammation and nigrostriatal degeneration using the rat α-syn PFF model. Background: No therapy exists to halt or slow…In silico predictive analytics: accelerating identification of potential disease-modifying compounds for Parkinson’s disease
Objective: To use an in silico screen to identify compounds that have potential to reduce α-synuclein (aSyn) oligomers and are amenable to drug repurposing for…CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study
Objective: To test if alpha-synuclein (α-syn) levels in CSF, plasma and saliva predict PD status in the BioFind cohort, and to test whether α-syn levels…Alpha-synuclein enhances histone H3 lysine-9 dimethylation
Objective: To explore the nuclear function of alpha-synuclein (αS). Background: αS is a protein linked to Parkinson’s disease (PD) and related neurodegenerative disorders. It is…Salivary Alpha-Synuclein in Aging
Objective: We measured alpha-synuclein total (a-syntotal) and alpha-synuclein oligomers (a-synolig) concentration in 70 healthy subjects, of different ages (from 18 to 88 years old) to…Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia
Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…Extracellular alpha-synuclein internalizes into cells by hijacking endocytic trafficking of dopamine transporter
Objective: The main purposes of this study were to: 1) investigate the possible effect of extracellular alpha-synuclein (aSYN) on the endocytic rate of dopamine transporter…
- « Previous Page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- …
- 60
- Next Page »